Abdominal Infection
Conditions
Keywords
sepsis shock, Tigecycline, Piperacillin / tazobactam, Abdominal infection
Brief summary
Selection of tigecycline in severe sepsis and septic shock patients in empirical antibiotic therapy (Hai Zheng Energy Star ®) combined with piperacillin / tazobactam (tazocin ®) scheme, compared with the classical scheme, evaluate its efficacy, safety index.
Detailed description
Tigecycline as representative glycylcycline antibiotics, has wide antibacterial spectrum and strong antibacterial activity, tigecycline in almost all of the gram positive bacteria and most gram negative bacteria and atypical pathogens, anaerobic bacteria are very good antibacterial activity except Pseudomonas aeruginosa, Proteus. Safety on organ function, in patients with renal insufficiency or in dialysis patients, no dose adjustment is required application of tigecycline, mild to moderate hepatic insufficiency patients do not need to adjust the dose of tigecycline. Piperacillin / tazobactam also is a broad spectrum, potent antibiotics, especially strong bactericidal activity against Pseudomonas aeruginosa, including resistant enzyme producing gram negative bacilli, in accordance with its pharmacokinetic pharmacodynamic characteristics of prolonged infusion time can obtain a stronger bactericidal activity. These two potent drugs have broad antimicrobial spectrum, strong bactericidal activity, and provide for the treatment of severe sepsis and septic shock a new choice in antibiotic selection, to a certain extent reduces the resistance pressure, and have more clinical safety.
Interventions
DRUGglycopeptide plus carbapenem
The control group antibiotic selection according to the classical scheme use of glycopeptide plus carbapenem antibiotic (or oxazolidinone antibiotics), with or without antifungal therapy
DRUGHaizheng Li Xing ® plus tazocin ®
Tigecycline (Haizheng Li Xing ®) combined with piperacillin/tazobactam (tazocin ®), with or without antifungal therapy
Sponsors
Zhejiang Hisun Pharmaceutical Co. Ltd.
Tianjin Medical University Cancer Institute and Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Be consistent with severe sepsis and septic shock diagnosis standards * Age above 18 years old, is expected in more than 5 days in ICU * APACHEⅡ score\>15 * By the patients themselves or their authorized person agreed to participate in the clinical trial and signed the informed consent
Exclusion criteria
* Allergic to penicillin, or of tigecycline allergic patients * Patients with abnormal liver function is severe * Be pregnant or lactating women * Be not signed the informed consent of patients * Any can be expected to increase patient risk or other factors can interfere with the results of a clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of treatment between Tigecycline plus tazocin and classic anti infection method | 2 weeks | Two groups of patients were assessed anti infection treatment effect per day. Including: temperature, procalcitonin, blood routine, liver and kidney function, bacteriological evidence, hemodynamics Effects of Haizheng Li Xing ® combined with tazocin ® in clinical treatment is not inferior to the classical antibiotics scheme |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Successful rate between two groups with abnormal renal function and liver function abnormalities which should adjust dose of drugs | 2 weeks | Evaluation of two groups of patients EGDT treatment compliance rate, mortality rate (the success rate of treatment), ICU stay time. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Residence time and expenses in ICU | 2 weeks | Patients with ICU residence time and expenses have no difference between the two groups. |
Countries
China
Contacts
Primary ContactWang Donghao, chief
Outcome results
None listed